XPH Quote, Financials, Valuation and Earnings

Range Cancer Therapeutics ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Range Cancer Therapeutics ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.747, which suggesting that the stock is 25.271% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.282%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.58%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.747, which suggesting that the stock is 25.271% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.832, suggesting its less volatile than the S&P 500 by 16.774%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.58%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

Direxion Daily Pharmaceutical & Medical Bl 3X Shs has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Direxion Daily Pharmaceutical & Medical Bl 3X Shs's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily Pharmaceutical & Medical Bl 3X Shs has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Direxion Daily Pharmaceutical & Medical Bl 3X Shs, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Direxion Daily Pharmaceutical & Medical Bl 3X Shs.

SPDR S&P Pharmaceuticals ETF has a beta of 0.747, which suggesting that the stock is 25.271% less volatile than S&P 500. In comparison Direxion Daily Pharmaceutical & Medical Bl 3X Shs has a beta of 2.200, suggesting its more volatile than the S&P 500 by 119.998%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.58%. Direxion Daily Pharmaceutical & Medical Bl 3X Shs offers a yield of 1.25% to investors and pays a quarterly dividend of $0.01 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Direxion Daily Pharmaceutical & Medical Bl 3X Shs pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Direxion Daily Pharmaceutical & Medical Bl 3X Shs quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Direxion Daily Pharmaceutical & Medical Bl 3X Shs's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Direxion Daily Pharmaceutical & Medical Bl 3X Shs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Direxion Daily Pharmaceutical & Medical Bl 3X Shs. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Health Care Services ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than SPDR S&P Health Care Services ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.747, which suggesting that the stock is 25.271% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.067, suggesting its more volatile than the S&P 500 by 6.681%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.58%. SPDR S&P Health Care Services ETF offers a yield of 0.36% to investors and pays a quarterly dividend of $0.08 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.